Compare TG Therapeutics Inc (TGTX) vs United States Oil ETF (USO) Price & Performance

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

USO trades at $127.30, up 1.1% today, with a bullish technical outlook supported by moving averages. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. Key support lies at $126, with resistance at $129.

The stock faces upside from supply constraints but risks include demand weakness and geopolitical uncertainty. Investors should weigh bullish technicals against fundamental headwinds in oil markets for balanced positioning.